Meiyu Fang

Dr. Meiyu Fang

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019
Verified
Journal Article
Closed access
JCJun Cao
Jun Cao
JWJiale Wang
Jiale Wang
CHChiyu He
Chiyu He
MFMeiyu Fang
Meiyu Fang

1 July 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
JCJun Cao
Jun Cao
MZMengdi Zhang
Mengdi Zhang
BWBin Wang
Bin Wang
LZLong Zhang
Long Zhang
FZFangfang Zhou
Fangfang Zhou
MFMeiyu Fang
Meiyu Fang
Breast cancer is the most common malignant tumor in females worldwide. Chemotherapy is the standard breast cancer treatment; however, chemoresistance is often seen in patients with metastatic breast cancer. Owing to high heterogeneity, the mechanisms of breast cancer chemoresistance and metastasis have not been fully investigated. The possible molecular mechanisms of chemoresistance in breast cancer include efflux transporters, signaling pathways, non-coding RNAs, and cancer stem cells. However, to overcome this hurdle, the use of novel clinical strategies such as drug carriers, immunotherapy, and autophagy regulation, are being investigated. The goal of this review is to summarize the current data about the molecular mechanisms of breast cancer chemoresistance and the novel clinical strategies; thus, providing a useful clinical tool to explore optimal treatment for breast cancer.

1 January 2021 in Cancer Letters
Verified
Journal Article
Open access
JCJun Cao
Jun Cao
MZMengdi Zhang
Mengdi Zhang
LZLong Zhang
Long Zhang
JLJianlin Lou
Jianlin Lou
FZFangfang Zhou
Fangfang Zhou
MFMeiyu Fang
Meiyu Fang
Thyroid cancer is the most common endocrine malignant tumor, and its incidence has increased significantly in the past few years. A growing number of noncoding RNAs (ncRNAs) have shown abnormal expression patterns in human thyroid cancer in recent studies. Depending on size, ncRNAs are usually subdivided into two categories: short ncRNAs and long ncRNAs (longer than 200 nucleotides). Short ncRNAs include microRNAs (miRNAs), PIWI-interacting RNAs, small nucleolar RNAs, and endogenous small interfering RNAs, which have been extensively studied due to their roles in developmental and tumor biology. Compared to that of short ncRNAs, the involvement of lncRNAs in human cancers, especially in thyroid cancer, is not as well studied. Here, we reviewed the roles and clinical significance of miRNAs, lncRNAs, and circular RNA in thyroid development, tumorigenesis, and metastasis to offer a new approach to thyroid cancer treatment.

21 September 2023 in eClinicalMedicine
Verified
Journal Article
Open access
BXBushu Xu
Bushu Xu
QPQiuzhong Pan
Qiuzhong Pan
HPHua Pan
Hua Pan
HLHaomiao Li
Haomiao Li
XLXianan Li
Xianan Li
XZXing Zhang
Xing Zhang
No standard maintenance treatment has been obtained to prolong the response duration of soft tissue sarcoma (STS) after first-line chemotherapy. In this study, we aimed to evaluate the efficacy and safety of anlotinib as a maintenance treatment after chemotherapy in STS. In this multicentre, open-label, single-arm phase 2 trial, patients with advanced STS who achieved partial response or stable disease after first-line anthracycline-based chemotherapy were enrolled between April 2019 and January 2022. All patients received anlotinib as a maintenance treatment. The primary endpoint was progression-free survival (PFS) of anlotinib maintenance treatment. Other endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety. This study is registered with ClinicalTrials.gov, NCT03890068. At the data cut-off date (August 8, 2022), 49 patients were enrolled, including 17 with liposarcoma (35%) and 15 with leiomyosarcoma (31%). After a median follow-up of 17.1 months (IQR 9.0–27.2), the median PFS from the beginning of maintenance treatment was 9.1 months (95% CI 5.7–12.5), and the median OS was not reached, and the 1-year OS rate for anlotinib maintenance treatment was 98.0%. The best ORR and DCR were 16% (8/49, 95% CI 7–30) and 94% (46/49, 95% CI 83–99), respectively. Most of the treatment-related adverse events were grade 1–2. Of the grade 3–4 adverse events, the most common were hypertension (10%) and hand-foot syndrome reaction (6%). Postchemotherapy maintenance treatment with anlotinib exhibits promising efficacy and tolerable toxicity in patients with advanced STS. Chia Tai Tianqing Pharmaceutical Group Co., Ltd., the 10.13039/501100012166 National Key Research and Development Program of China , and the 10.13039/501100001809 National Natural Science Foundation of China .

1 December 2020 in Cancer Letters
Verified
Journal Article
Open access
JCJun Cao
Jun Cao
MZMengdi Zhang
Mengdi Zhang
FXFeng Xie
Feng Xie
JLJianlin Lou
Jianlin Lou
XZXiaoxue Zhou
Xiaoxue Zhou
FZFangfang Zhou
Fangfang Zhou
Exosomes are extracellular vesicles with a diameter of 30-100 nm that exist stably in various body fluids, including the blood, cerebrospinal fluid, urine, saliva, and serous cavity effusion. Compared with other vesicles, exosomes have a unique double-layer saclike structure and an endosomal origin. Depending on the physiological state of donor cells, there is heterogeneity in the bioactive substances present in exosomes, including proteins, RNA, DNA, lipids, and metabolites, providing a rich source of potential biomarkers for disease diagnosis. In head and neck cancer (HNC), exosomes have applications in disease diagnosis and prognosis based on liquid biopsy. Nonetheless, the functions and mechanisms of exosomes in HNC still remain unclear. Recent studies have elucidated the substances and signals transmitted between cancer cells using exosomes and have discussed tumor occurrence, development, metastasis, immune regulation, and drug resistance regulated by exosomes in HNC. In this review, we discuss these recent findings and highlight the significant role of exosomes in HNC, with a focus on the mechanism of tumor progression and the potential clinical value of exosomes as biomarkers and therapeutic targets.

31 August 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LMLili Mao
Lili Mao
MFMeiyu Fang
Meiyu Fang
YCYu Chen
Yu Chen
XWXiaoting Wei
Xiaoting Wei
JCJun Cao
Jun Cao
LSLu Si
Lu Si
Purpose: Anti–programmed cell death-1 monotherapy is part of standard therapy for cutaneous melanoma but has low efficacy in mucosal melanoma. We evaluated the efficacy and safety of atezolizumab plus bevacizumab as first-line therapy for advanced mucosal melanoma. Patients and Methods: This multicenter, open-label, single-arm, phase II study used a Simon's two-stage design. Atezolizumab (fixed-dose, 1,200 mg) and bevacizumab (7.5 mg/kg) were administered by intravenous infusion every 3 weeks. The primary endpoint was objective response rate (ORR), determined per RECIST v1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response (DOR), and safety, with adverse events (AE) summarized using NCI-CTCAE v5.0. Results: Overall, 43 patients were enrolled, including 20 (46.5%) with unresectable and 23 (53.5%) with metastatic mucosal melanoma. Median follow-up was 13.4 months at data cutoff (July 30, 2021). Forty patients were evaluable for response: ORR was 45.0% [95% confidence interval (CI), 29.3%–61.5%; one complete response, 17 partial responses]. Median PFS was 8.2 months (95% CI, 2.7–9.6); 6- and 12-month PFS rates were 53.4% (95% CI, 36.6%–67.6%) and 28.1% (95% CI, 14.2%–43.9%), respectively. Median OS was not reached (NR; 95% CI, 14.4–NR). Six- and 12-month OS rates were 92.5% (95% CI, 78.5%–97.5%) and 76.0% (95% CI, 57.1%–87.5%), respectively. Median DOR was 12.5 months (95% CI, 5.5–NR). Overall, 90.7% (39/43) of patients experienced treatment-related AEs; 25.6% (11/43) experienced grade ≥3 events. Conclusions: Atezolizumab in combination with bevacizumab showed promising efficacy and manageable safety in patients with advanced mucosal melanoma.